A5030690238- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Single-cell and spatial transcriptomics
- COVID-19 and healthcare impacts
- Genomics and Phylogenetic Studies
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Molecular Biology Techniques and Applications
- Immune Cell Function and Interaction
- Monoclonal and Polyclonal Antibodies Research
- Estrogen and related hormone effects
- Genomics and Rare Diseases
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- COVID-19 Clinical Research Studies
- DNA and Nucleic Acid Chemistry
- Effects and risks of endocrine disrupting chemicals
- melanin and skin pigmentation
- SARS-CoV-2 and COVID-19 Research
- Cancer Research and Treatments
- Male Breast Health Studies
- Skin Protection and Aging
- Endometriosis Research and Treatment
- Hematopoietic Stem Cell Transplantation
- Colorectal Cancer Screening and Detection
New York Genome Center
2020-2025
Memorial Sloan Kettering Cancer Center
2020-2025
Kettering University
2023-2024
Cornell University
2018-2020
Weill Cornell Medicine
2020
Columbia University Irving Medical Center
2016-2017
Stanford University
2008-2009
Universidade de São Paulo
1987
Patients with cancer have high mortality from coronavirus disease 2019 (COVID-19), and the immune parameters that dictate clinical outcomes remain unknown. In a cohort of 100 patients who were hospitalized for COVID-19, hematologic had higher relative to solid cancer. two additional cohorts, flow cytometric serologic analyses demonstrated without similar phenotype during acute whereas impairment B cells severe respiratory syndrome 2 (SARS-CoV-2)-specific antibody responses. Despite impaired...
Cancer patients have increased morbidity and mortality from Coronavirus Disease 2019 (COVID-19), but the underlying immune mechanisms are unknown. In a cohort of 100 cancer hospitalized for COVID-19 at University Pennsylvania Health System, we found that with hematologic cancers had significantly higher relative to solid after accounting confounders including ECOG performance status active status. We performed flow cytometric serologic analyses 106 113 non-cancer controls two additional...
The presence of circulating tumor DNA (ctDNA) in patients with colorectal adenomas remains uncertain. Studies using tumor‐agnostic approaches report ctDNA 10–15% patients, though uncertainty as to whether the signal originates from adenoma. To obtain an accurate estimate proportion ctDNA, a sensitive tumor‐informed strategy is preferred, it ensures detected Here, whole‐genome sequencing‐based analysis (MRD‐EDGE SNV ) was applied two independent cohorts. Cohort 1, comprising 93 stage III...
Inhibitors of soluble adenylyl cyclase increase pigmentation and may reduce the risk skin cancer.
Background: Whether COVID-19 vaccination and the associated immune response increases susceptibility to immune-related adverse events (irAEs) among patients treated with checkpoint inhibition (ICI) remains unknown. Short-term follow-up can assess safety of concurrent administration vaccine ICI treatment. Methods: We conducted an electronic health record analysis a cohort 408 cancer receiving therapy who were vaccinated for between January 16 March 27, 2021. Patients seen in 90 days from day...
ABSTRACT In solid tumor oncology, circulating DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity ctDNA fragments in low fraction (TF) settings increase MRD sensitivity, we previously leveraged genome-wide mutational integration plasma whole genome sequencing (WGS). We now introduce MRD-EDGE, a composite machine learning-guided WGS single nucleotide variant (SNV) copy number (CNV)...
Objectives Nivolumab has recently been shown in the phase III clinical trial CheckMate‐141 to have superior survival rates compared current standard of care chemotherapy for recurrent or metastatic platinum‐resistant head and neck squamous cell carcinoma (HNSCC). targets immune inhibitory receptor programmed death 1 (PD‐1). Programmed ligand (PD‐L1) genomics poorly characterized context HNSCC, including expression levels PD‐L1 individual tumors as well related up down‐regulated genes that...
ABSTRACT Circulating cell-free DNA (ccfDNA) sequencing for low-burden cancer monitoring is limited by sparsity of circulating tumor (ctDNA), the abundance genomic material within a plasma sample, and pre-analytical error rates due to library preparation, errors. Sequencing costs have historically favored development deep targeted approaches overcoming in ctDNA detection, but these techniques are ccfDNA samples, which imposes ceiling on maximal depth coverage panels. Whole genome (WGS) an...
Abstract Several approaches for the detection of circulating tumor DNA (ctDNA) are anchored in accurate identification cancer-specific single nucleotide variants (SNVs) plasma. Such limited ultra-low fraction (TF) contexts, such as early cancer or postoperative minimal residual disease, where ctDNA SNVs difficult to distinguish against background sequencing error. these critical low TF contexts is further by sparse amount cell free (cfDNA) plasma (Zviran et al., 2020). To reduce...
Abstract Individual bulk tumor biopsies are invasive and may fail to capture clonal heterogeneity within primary tumors metastatic sites of disease. Further, analyses subclonal variants often hindered by background error rates related tissue preservation methods (e.g. FFPE) sequencing artifact. Use plasma-only ultrasensitive liquid biopsy approaches allow for noninvasive inference clonality dynamically track changes in burden. We previously developed MRD-EDGE, a tumor-informed machine...
e23132 Background: Personalized medicine in oncology is increasingly available due to the development of more targeted therapies as well decreasing expense and rapid results next generation sequencing (NGS). At Columbia University Medical Center, patients undergo genomic profiling with a NGS assay called Combined Cancer Panel (CCCP). We sought assess frequency actionable alterations identified across tumor types. Methods: The CCCP can detect 467 tumor-specific genes exons. are categorized...
Abstract In many areas of oncology, we lack sensitive tumor-burden monitoring to guide critical decision making. While circulating tumor DNA (ctDNA) promises enable disease monitoring, this approach is limited by the sparsity ctDNA in plasma. To overcome challenge, error-corrected deep targeted sequencing has been proposed. Nonetheless, framework low number genomic equivalents (GEs, ~103/mL plasma), imposing a ceiling on effective depth. We have previously shown that genome-wide mutational...
<h3>Background</h3> Clearance of circulating tumor DNA (ctDNA) following checkpoint blockade (CB) can precede radiographic response,<sup>1 2</sup> though current state the art ctDNA detection via targeted panels faces limited sensitivity in low burden disease (figure 1). We previously showed that whole genome sequencing (WGS) plasma overcome input to dynamically track volume malignancy using matched tissue.<sup>3</sup> therefore sought evaluate for tracking early response melanoma, and...